NCT05327166 (ED-LINC2) is a NA clinical trial of ED-LINC in Opioid Use Disorder, sponsored by University of Washington.

Who is sponsoring NCT05327166?

NCT05327166 is sponsored by University of Washington.

What drugs are being tested in NCT05327166?

Interventions in NCT05327166: ED-LINC.

What condition does NCT05327166 study?

NCT05327166 studies Opioid Use Disorder.

Is NCT05327166 still recruiting?

NCT05327166 is currently active, enrolled. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT05327166: ED-LINC2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Emergency Department Longitudinal Integrated Care

Active, enrolled NA Last updated 10 December 2025

What this trial tests

NA trial testing ED-LINC in Opioid Use Disorder in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

12 April 2022

Primary endpoint
31 May 2026

31 December 2026

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	500
Start date	12 April 2022
Primary completion	31 May 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

ED-LINC

Conditions studied

Opioid Use Disorder — all drugs for Opioid Use Disorder →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Collaborative care is a comprehensive patient-centered model of healthcare delivery targeting behavioral health or substance use that stems from the chronic disease management framework. The intervention being tested ('Emergency Department Longitudinal Integrated Care' or ED LINC) derives from the collaborative care model and has demonstrated feasibility in previous studies. This study expands on the model to test the effectiveness of the ED-LINC intervention when compared with usual care. The study team primarily hypothesizes that patients randomized to the ED-LINC intervention, when compared to patients randomized to usual care, will demonstrate: 1) significant reductions in self-report illicit opioid use, 2) significant increases in initiation and retention of medications for opioid use disorder, and 3) significant reductions in ED utilization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adapting to the Fentanyl Epidemic: Rapid Qualitative Observations and Derived Clinical and Research Implications from the Emergency Department Longitudinal Integrated Care (ED-LINC) Randomized Clinical Trial.
Lovett K, Zatzick D, Palinkas LA, Engstrom A, et al · · 2025 · PMID 40100166 · DOI 10.1080/00332747.2025.2472429

Verify or expand the search:

Other trials of ED-LINC

Trials testing the same drug.

NCT03699085 — Emergency Department Longitudinal Integrated Care · NA · completed

Other recruiting trials for Opioid Use Disorder

Currently open trials in the same condition.

NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05327166 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05327166.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing